OpenURL Connection Search

Select item for more details and to access through your institution.

Cystic form of paraduodenal pancreatitis (cystic dystrophy in heterotopic pancreas (CDHP)): a potential link with minor papilla abnormalities? A study in a large series.
Published in:
2016
By:
- Wagner, M.;
- Vullierme, M.;
- Rebours, V.;
- Ronot, M.;
- Ruszniewski, P.;
- Vilgrain, V.;
- Vullierme, M P
Publication type:
journal article
ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.
Published in:
Neuroendocrinology, 2017, v. 105, n. 3, p. 310, doi. 10.1159/000458155
By:
- Knigge, U.;
- Capdevila, J.;
- Bartsch, D.K.;
- Baudin, E.;
- Falkerby, J.;
- Kianmanesh, R.;
- Kos-Kudla, B.;
- Niederle, B.;
- Nieveen van Dijkum, E.;
- O'Toole, D.;
- Pascher, a.;
- Reed, N.;
- Sundin, a.;
- Vullierme, M.-P.
Publication type:
Article
Primary endocrine tumours of the liver.
Published in:
British Journal of Surgery, 2005, v. 92, n. 10, p. 1255, doi. 10.1002/bjs.5073
By:
- Maire, F.;
- Couvelard, A.;
- Vullierme, M. P.;
- Kianmanesh, R.;
- O'Toole, D.;
- Hammel, P.;
- Belghiti, J.;
- Ruszniewski, P.
Publication type:
Article
Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.
Published in:
British Journal of Cancer, 2007, v. 96, n. 1, p. 49, doi. 10.1038/sj.bjc.6603526
By:
- Marrache, F.;
- Vullierme, M. P.;
- Roy, C.;
- Assoued, Y. El;
- Couvelard, A;
- O'Toole, D.;
- Mitry, E.;
- Hentic, O.;
- Hammel, P.;
- Lévy, P.;
- Ravaud, P.;
- Rougier, P.;
- Ruszniewski, P.
Publication type:
Article

Found: 4

Cystic form of paraduodenal pancreatitis (cystic dystrophy in heterotopic pancreas (CDHP)): a potential link with minor papilla abnormalities? A study in a large series.

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.

Primary endocrine tumours of the liver.

Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.